Skip to content

Efficacy and safety analysis of Vericiguat in the treatment of acute heart failure patients: a multicenter, randomized controlled, open label clinical study (VERIFAST study)

Efficacy and safety analysis of Vericiguat in the treatment of acute heart failure patients: a multicenter, randomized controlled, open label clinical study (VERIFAST study)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119472
Enrollment
Unknown
Registered
2026-02-27
Start date
2026-03-06
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute heart failure

Interventions

Control Group:GDMT Standard Heart Failure Treatment
Experimental Group:GDMT Standard Heart Failure Treatment+Take vericiguat.

Sponsors

Shanghai Tenth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Male and female patients aged >18 years who can understand and sign informed consent forms; 2.Hospitalization due to acute heart failure (meeting at least two of the following criteria): (1) dyspnea and/or fatigue symptoms (2) physical examination found evidence of fluid retention (lung moist rale, jugular vein rage, peripheral edema) (3) chest X-ray showed pulmonary congestion (4) NT proBNP increased (sinus rhythm >= 1000 pg/ml); Atrial fibrillation >= 1600 pg/ml); 3.Left ventricular ejection fraction= 100 mmHg (4) heart rate <=120 beats per minute (5) respiratory rate <=25 beats per minute without oxygen inhalation;

Exclusion criteria

Exclusion criteria: 1.eGFR<15 ml/min/1.73m ² (using MDRD formula); 2.Severe liver dysfunction (Child Pugh C grade); 3.Simultaneously or anticipated use of the following drugs: (1) long-acting nitrate drugs, (2) other sGC stimulators, (3) phosphodiesterase-5 inhibitors (such as sildenafil, tadalafil); 4.Continuous use of intravenous inotropic drugs is required; 5.Implantable left ventricular assist device; 6.Plan to undergo a heart transplant within 3 months; 7.Severe primary pulmonary arterial hypertension; 8.acute pulmonary embolism; 9.Severe anemia (hemoglobin<60 g/dL); 10.Pregnant or lactating women; 11.Non cardiovascular diseases with an expected survival period of less than 12 months; 12.Participate in other interventional clinical trials;

Design outcomes

Primary

MeasureTime frame
NT-proBNP;

Secondary

MeasureTime frame
Left ventricular remodeling and function;6-minute walking distance;readmission due to heart failure;all-cause mortality;

Countries

China

Contacts

Public ContactShuqin Zhou

Shanghai Tenth People’s Hospital

shuqinzhou@tongji.edu.cn+86 181 2118 6315

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026